Supportive Therapy in OncologySupportive Therapy in OncologyПоддерживающая терапия в онкологии3034-24733034-3178Publishing House ABV Press8510.17650/3034-2473-2026-3-1-30-34ORIGINAL REPORTSОРИГИНАЛЬНЫЕ СТАТЬИResearch ArticleCytostatic extravasation: a modern view on prevention, management and staff educationЭкстравазация цитостатиков: современный взгляд на профилактику, лечение и обучение персоналаSatirovaElena F.СатироваЕлена Федоровна
Russian Federation
lena.satirova@mail.ru"Our Time" ClinicКлиника «Наше время»260620263130342806202628062026Copyright ©; 2026, ABV-PressCopyright ©; 2026, АБВ-пресс2026ABV-PressАБВ-прессhttps://creativecommons.org/licenses/by/4.0/https://stio.abvpress.ru/jour/article/view/85

Cytostatic extravasation is a rare but severe complication of chemotherapy administration. This article reviews current prevention and treatment strategies according to international (ESMO, MASCC, NCCN) and Russian recommendations. The mechanisms of tissue injury are discussed for different drug classes, including anthracyclines, vinca alkaloids, taxanes, and platinum agents. A step-by-step algorithm and detailed table of antidotes (dexrazoxane, hyaluronidase, sodium thiosulfate, DMSO) are presented. The article highlights practical implementation issues in Russian clinics, where lack of standardized extravasation kits and antidotes remains a problem. Early recognition, staff training, and safety culture are key to reducing complications.

Экстравазация цитостатиков – редкое, но потенциально тяжелое осложнение противоопухолевой терапии. В статье представлен современный подход к профилактике и лечению экстравазации с учетом международных рекомендаций (ESMO, MASCC, NCCN) и российских реалий. Особое внимание уделено алгоритмам действий медицинского персонала, описаны механизмы повреждения тканей различными группами цитостатиков, приведены схемы применения антидотов, включая дексразоксан, и практические аспекты организации безопасной инфузионной терапии в онкологии.

extravasationcytostaticschemotherapy complicationssupportive therapydexrazoxanestaff trainingэкстравазацияцитостатикиосложнения химиотерапииподдерживающая терапиядексразоксанобучение персоналаPérez Fidalgo J.A., García Fabregat L., Cervantes A. et al. ESMO Guidelines Working Group. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol 2012;23(Suppl 7):167–73. DOI: 10.1093/annonc/mds294Mouridsen H.T., Langer S.W., Buter J. et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol 2007;18(3):546–50. DOI: 10.1093/annonc/mdl413Schulmeister L. Extravasation management: clinical update. Semin Oncol Nurs 2011;27(1):82–90. DOI: 10.1016/j.soncn.2010.11.010Bertelli G., Gozza A., Forno G.B. et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 1995;13(11):2851–5. DOI: 10.1200/JCO.1995.13.11.2851Kreidieh F.Y., Moukadem H.A., El Saghir N.S. Overview, prevention and management of chemotherapy extravasation. World J Clin Oncol 2016;7(1):87–97. DOI: 10.5306/wjco.v7.i1.87Kimmel J., Fleming P., Cuellar S. et al. Pharmacological management of anticancer agent extravasation: a single institutional guideline. J Oncol Pharm Pract 2018;24(2):129–38. DOI: 10.1177/1078155217690924Sauerland C., Engelking C., Wickham R., Corbi D. Vesicant extravasation part I: Mechanisms, pathogenesis, and nursing care to reduce risk. Oncol Nurs Forum 2006;33(6):1134–41. DOI: 10.1188/06.ONF.1134-1141Matsumoto K., Ryushima Y., Sato J. et al. Extravasation associated with cancer drug therapy: multidisciplinary guideline of the Japanese Society of Cancer Nursing, Japanese Society of Medical Oncology, and Japanese Society of Pharmaceutical Oncology. ESMO Open.2024;9(10):103932. DOI: 10.1016/j.esmoop.2024.103932Thomas T., Clark C., Backler C. et al. ONS/ASCO Guideline on the management of antineoplastic extravasation. Clin J Oncol Nurs 2025;29(5):384–99. DOI: 10.1188/25.CJON.384-399Langer S.W. Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer Manag Res 2014;6:357–63. DOI: 10.2147/CMAR.S47238Pérez-Fidalgo J.A., Cervantes A. Comment on: management of chemotherapy extravasation: ESMO-EONS Clinical practice guidelines. Ann Oncol 2013;24(4):1129–30. DOI: 10.1093/annonc/mdt024Kane R.C., McGuinn W.D. Jr, Dagher R. et al. Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy. Oncologist 2008;13(4):445–50. DOI: 10.1634/theoncologist.2007-0247Conde-Estévez D., Mateu-de Antonio J. Treatment of anthracycline extravasations using dexrazoxane. Clin Transl Oncol 2014;16(1):11–7. DOI: 10.1007/s12094-013-1100-7Pericay C., López A., Soler J.R. et al. Extravasation of oxaliplatin: an infrequent and irritant toxicity. Clin Transl Oncol 2009;11(2):114–6. DOI: 10.1007/s12094-009-0324-zBuidenok Yu.V., Obukhova O.A. Practical recommendations for the prevention and treatment of the effects of extravasation of antitumor drugs. Malignant tumors: Practical recommendations RUSSCO. 2024. Vol. 14, No. 3s2. Available by: https://www.rosoncoweb.ru/standarts/RUSSCO/ 2024/2024-2-13.pdfБуйденок Ю.В., Обухова О.А. Практические рекомендации по профилактике и лечению последствий экстравазации противоопухолевых препаратов. Злокачественные опухоли: Практические рекомендации RUSSCO. 2024. Т. 14, № 3s2. Доступно по: https://www.rosoncoweb.ru/standarts/RUSSCO/ 2024/2024-2-13.pdfEuropean Oncology Nursing Society (EONS). Extravasation Guidelines 2007. EONS, Brussels. Eur J Oncol Nurs 2008;12(4):357–61. DOI: 10.1016/j.ejon.2008.07.003Буйденок Ю. В. Рекомендации по профилактике и лечению последствий экстравазации противоопухолевых препаратов. Злокачественные опухоли: Практические рекомендации RUSSCO 2024;(14):171–81. DOI: 10.18027/2224-5057-2024-14-3s2-171-181